The San Francisco-based startup InsightRX is determined to provide an individualized understanding of a patient’s response to treatment, and has developed a software platform that help guide treatment decision-making. The clinical decision support tool leverage mathematical models, patient demographics, physiological characteristics, genomic data, drug concentrations and biomarkers to calculate drug and dose recommendations. Drug concentration and biomarker data are collected over time to get a deeper understanding of patient response, enabling treatment optimization. And as more data is collected, the algorithms that guide the treatment recommendations will learn and become more precise. The technology is available as an easy-to-use, cloud-based web application that can be accessed directly through the electronic medical record at the point-of-care. It is currently being developed for a handful of drugs, but the software will eventually be applied to a broad range of medications.
The ‘one-size-fits-all’ approach to drug design and treatment results in hundreds of thousands of deaths each year, and billions of dollars in costs. That’s because how much of a drug enters the bloodstream and how quickly it exits the body is influenced by multiple individual factors, such as patient demographics or genetics. And with so many variables, choosing the best medication and dose can be a matter of trial and error. InsightRX’s innovative technology help personalize treatment, including how much to take, how frequently, and for how long. For some patients, taking half a dose four times a day might work much better than full doses twice a day.
Although developing these models to optimize dosing is a complex process that needs to be refined and validated through clinical trials, a more precise, personalized approach could have a major impact on patient care and health outcomes. It could improve treatment efficacy, reduce side effects, and prevent thousands of deaths each year. In fact, multiple studies have shown that individualized dosing lead to significantly better survival rates and improved outcomes, and could potentially help reduce associated healthcare costs.
InsightRX is a spin-off from UCSF and was founded in 2015 by Sirj Goswami, Ron Keizer and Ranvir Mangat. The startup has partnered with multiple clinical centers, including UCSF and Stanford Medical Center, to pilot their technology, and has previously received a grant from the Clinical & Translational Science Institute at UCSF. They have also raised a seed funding round with an undisclosed amount from Launchpad Digital Health and Plug&Play, two accelerator programs based in San Francisco and Sunnyvale, CA.